EHA 2019 Adam Mead, MD, PhD

Adam Mead, MD, PhD from the John Radcliffe Hospital, Oxford, UK commenting on the publication REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY, which was presented at EHA 2019 in Amsterdam

EHA Library. Mead A. Jun 15, 2019; 266799

https://library.ehaweb.org/eha/2019/24th/266799/adam.mead.real.world.tyrosine.kinase.inhibitor.treatment.pathways.monitoring.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DREAL+WORLD+TYROSINE+KINASE+INHIBITOR+TREATMENT+PATHWAYS%2C+MONITORING+PATTERNS+AND+RESPONSES+COMPARED+WITH+ELN+RECOMMENDATIONS+IN+CHRONIC+MYELOID+LEUKAEMIA%3A+FINAL+ANALYSIS+OF+THE+UK+TARGET+CML+STUDY

Related items